Compare BEAM & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAM | CPRI |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2020 | 2011 |
| Metric | BEAM | CPRI |
|---|---|---|
| Price | $31.65 | $24.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $46.00 | $27.08 |
| AVG Volume (30 Days) | 2.0M | ★ 2.1M |
| Earning Date | 02-24-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $55,701,000.00 | ★ $4,369,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.52 | $2.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.53 | $11.86 |
| 52 Week High | $36.44 | $28.27 |
| Indicator | BEAM | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 45.79 |
| Support Level | $29.80 | $24.17 |
| Resistance Level | $35.34 | $26.26 |
| Average True Range (ATR) | 2.80 | 0.97 |
| MACD | 0.14 | -0.13 |
| Stochastic Oscillator | 55.79 | 17.46 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.